Adaptimmune Therapeutics (NASDAQ:ADAP) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.
A number of other equities analysts have also commented on ADAP. TheStreet upgraded shares of Adaptimmune Therapeutics from a “d” rating to a “c” rating in a report on Thursday, November 2nd. Zacks Investment Research lowered shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 10th. ValuEngine lowered shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. SunTrust Banks reiterated a “buy” rating and issued a $10.00 price objective on shares of Adaptimmune Therapeutics in a report on Thursday, October 12th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $15.00 price objective on shares of Adaptimmune Therapeutics in a report on Friday, September 8th. Two analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $11.58.
Adaptimmune Therapeutics (NASDAQ:ADAP) opened at $7.06 on Wednesday. Adaptimmune Therapeutics has a 1-year low of $3.85 and a 1-year high of $9.29.
ILLEGAL ACTIVITY NOTICE: This report was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.com-unik.info/2017/12/22/adaptimmune-therapeutics-adap-rating-lowered-to-sell-at-bidaskclub.html.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
What are top analysts saying about Adaptimmune Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Adaptimmune Therapeutics and related companies.